Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More

Related Content

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Sanofi Working To Resolve GMP Issues That Derailed Sarilumab Approval

Oct 29 2016

J.P. Morgan Notebook Day 1: PCSK9 Face-Off, Teva’s Slowed Growth, Merck’s Keytruda Wins, Lilly’s CDK4/6 Hopes And More

Jan 10 2017

Biogen Spinraza Approval: The Perfect Antidote To Sarepta Headlines?

Jan 07 2017

Shire Plays Up Xiidra Launch, Downplays Missed Sales Expectations

Nov 01 2016

Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity

Oct 20 2016

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Oct 25 2016

Amicus Eyes Broad Future Label For Migalastat After Huge Filing Setback

Nov 30 2016

Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Oct 07 2016

Related Companies

Bristol Myers Squibb Company

Merck & Co., Inc.

Bristol Myers Squibb Company

Incyte Corporation

Sanofi

Regeneron Pharmaceuticals, Inc.

Biogen, Inc.

Ionis Pharmaceuticals, Inc.

Takeda Pharmaceutical Co. Ltd.

Allergan plc

Sarepta Therapeutics, Inc.

Anthem Inc.

Amicus Therapeutics, Inc.

Sanofi

Sanofi Genzyme

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Commercial Companies Business Strategies Drug Approval Standards Drug Review ImmunoOncology Launches Market Access Pricing Strategies Reimbursement BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window